V-Card | Print | PDF | Email Page

Scott D. Lyne
Partner

Contact

(T) +1.212.326.8382
(F) +1.212.755.7306

Education

  • Tulane University (J.D. magna cum laude 1999; Order of the Coif; Editor-in-Chief, Tulane Environmental Law Journal); The Cooper Union for the Advancement of Science and Art (M.E. in Chemical Engineering 1995; B.E. in Chemical Engineering 1992)

Bar Admissions

  • New York and registered to practice before the United States Patent and Trademark Office

Clerkships

  • Law Clerk to the Honorable Mariana R. Pfaelzer, United States District Court, Central District of California (1999-2000)

Scott Lyne's practice focuses on corporate transactions, licensing, and counseling involving intellectual property and technology. His experience includes the negotiation and structuring of intellectual property purchases and sales, technology development and licensing agreements, manufacturing, distribution and supply agreements, and the intellectual property and technology aspects of other corporate transactions, such as mergers and acquisitions, joint ventures, strategic alliances, asset securitizations, private equity investments, capital markets offerings, and secured lending.

In addition, Scott counsels clients on strategic intellectual property and technology matters, such as the development of strategies for the protection and exploitation of technologies and the enforcement of intellectual property rights, and works with clients on day-to-day operational issues relating to technology, intellectual property, electronic commerce, and privacy. He has worked with a wide range of clients in various industries, including public companies, as well as growing technology-driven businesses and start-ups.

Scott also has significant intellectual property litigation experience. He has represented domestic and foreign clients on matters involving diverse technologies, such as semiconductors, business methods, and physical and life sciences, and has experience with actions arising before the United States International Trade Commission and through the Abbreviated New Drug Application process.


Scott Lyne